IMR Press / FBL / Volume 23 / Issue 9 / DOI: 10.2741/4668

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

The biological and diagnostic role of mirna’s in hepatocellular carcinoma

Show Less
1 Department of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa
2 Faculty of Commerce, Law and Management, University of the Witwatersrand, Johannesburg, South Africa
3 UKZN Gastrointestinal Research Centre, Durban, South Africa
4 Basic Research Laboratory, Centre for Cancer Research, National Cancer Institute, Leidos Biomedical Research, Inc. Frederick Nat. Lab. for Cancer Research, Frederick, Maryland, USA
5 Medical Biochemistry, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa, University of KwaZulu-Natal, Durban, South Africa
6 Hertsen Moscow Oncology Research Institute, Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, 125284, Moscow, Russian Federation
7 Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991, Moscow, Russian Federation
Front. Biosci. (Landmark Ed) 2018, 23(9), 1701–1720; https://doi.org/10.2741/4668
Published: 1 March 2018
Abstract

The potential of exploitation of miRNA as diagnostic agents and therapeutic tools will likely only be realized when a complete knowledge of their biology is revealed. Despite more than a decade of research, the use of miRNA as diagnostic and therapeutic tools remains a ‘work in progress’. The objective of this review is to explore more recent developments in the role of deregulated miRNAs in hepatocellular carcinoma (HCC). This includes emerging insights involving miRNA biogenesis, their deregulation by cancer and their role in deregulating the principal HCC cancer pathways. Specific attention is directed at the role of deregulated miRNAs in HCC in a developing country context with high hepatitis B/C burden, as well as an examination of the challenges that confront the use of extracellular miRNAs as commercially viable diagnostic tools to detect early stage HCC.

Keywords
Micro RNA
miRNA
Deregulation
Hepatocellular Carcinoma
Biomarkers
Early Diagnosis
Review
Share
Back to top